



Europäisches Patentamt

European Patent Office

Office européen des brevets

⑪ Publication number:

0 261 283

A1

②

EUROPEAN PATENT APPLICATION

② Application number: 86307285.6

② Int. Cl.4: C07F 9/65 , C07F 9/24 ,
C08F 8/40 , C07H 21/00

② Date of filing: 22.09.86

Claims 13, 17, 18, 22, 23, 24, 25, 26, 27, 29, 30, 33, 34, 35, 36, 40, 45, 48, 51, 55, 56, 58, 60, 62, 63, 65, 68, 69, 70, 71, 73, 77 and 78 are deemed to be abandoned due to non-payment of the claims fees (Rule 31 (3) EPC).

④ Date of publication of application:
30.03.88 Bulletin 88/13

④ Designated Contracting States:
DE FR GB

⑦ Applicant: APPLIED BIOSYSTEMS, INC.
850 Lincoln Centre Drive
Foster City California 94404(US)


⑦ Inventor: Fung, Steven
765 San Antonio Road No. 8
Palo Alto, CA 94303(US)
Inventor: Woo, Sam Lee
450 Carlos Road
Redwood City, CA 94061(US)
Inventor: Smith, Lloyd M.
612 Meridian Avenue
South Pasadena, CA 91030(US)

⑦ Representative: Warden, John Christopher et al
R.G.C. Jenkins & Co. 12-15, Fetter Lane
London EC4A 1PL(GB)

⑤ Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors and useful conjugates thereof.

⑤ Compounds of the formulae :

EP 0 261 283 A1



wherein:

Xerox Copy Centre

n is in the range of 2 to 4;
n' is in the range of 2 to 3;
m is in the range of 1 to 3;
R₁ is an amino protection group;
R₂ and R₃ taken separately each represent hydrogen, lower alkyl, lower substituted alkyl, lower cycloalkyl, lower acyl, cyano, halo, or nitro; and
R₄ is alkyl, alkenyl, aryl, aralkyl, or cycloalkyl containing up to 10 carbon atoms, phosphoramidite precursors, and useful conjugates therof.

AMINO-DERIVATIZED PHOSPHITE AND PHOSPHATE LINKING AGENTS, PHOSPHORAMIDITE PRECURSORS, AND USEFUL CONJUGATES THEREOF

Background

5 The invention relates generally to organophosphorous compounds, and more particularly, to organophosphorous compounds for synthesizing amino-derivatized polymers, especially oligonucleotides.

Genes and gene control regions can now be routinely characterized and studied at the molecular level. This is possible because of several recent advances in the technology associated with manipulating and modifying deoxyribonucleic acid (DNA). Of particular importance have been advances in DNA sequencing, Maxam and Gilbert, "Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages," and Smith, 10 "DNA Sequence Analysis by Primed Synthesis," pgs. 499-560 and 560-580, respectively, in Methods in Enzymology, Grossman and Moldave, eds., Vol. 65 (Academic Press, New York, 1980); the isolation of a large number of host restriction modification enzymes, Roberts, "Dictionary of Restriction Endonucleases," in Methods in Enzymology, Wu, ed., Vol. 68 (Academic Press, New York, 1979); and the construction of vectors for cloning and amplifying defined DNA sequences, e.g. Bolivar and Backman, "Plasmids of E-scherichia coli Cloning Vectors," in Methods in Enzymology, Wu, ed., Vol. 68 (Academic Press, New York, 1979).

15 Many of these new techniques require that DNA fragments or oligonucleotides be labeled or attached to polymer supports. DNA sequencing techniques and gene probes, which can be used to help locate natural genes of commercial or scientific importance, require the use of labeled oligonucleotides. Until recently, all 20 DNA sequencing techniques relied on radioactive labels for distinguishing oligonucleotide fragments separated by electrophoresis. Radioactive labels are highly sensitive, and can be incorporated without steric hindrance, or other chemical side effects. However, their use poses a laboratory health hazard, which requires that they receive special handling and disposal. Moreover, their use is not amenable for rapid automatic sequencing of oligonucleotides, as nucleoside-specific radioactive labels are not available for 25 practical identification of different nucleotide bases, and radiation detection techniques such autoradiography and scintillation counting are too time consuming. As a consequence, other non-radioactive labeling techniques have been sought, such as fluorescent and colorimetric labeling, which depend on the ability to covalently link a fluorescent or chromogenic molecule to an oligonucleotide.

Chu et al, in "Derivatization of Unprotected Poly nucleotides," Nucleic Acids Research, Vol.11, pgs. 30 6513-6529(1983), disclose a method for attaching amines to the terminal 5'-phosphates of oligonucleotides. One object of the method is to provide a means for attaching organic labeling molecules to oligonucleotides by way of an amine linkage. The method involves treating the oligonucleotides with a carbodiimide.

35 Chollet and Kawashima, in "Biotin-Labeled Synthetic Oligodeoxyribonucleotides: Chemical Synthesis and Uses as Hybridization Probes," Nucleic Acids Research, Vol.13, pgs. 1529-1541 (1985), disclose the use of the method of Chu et al to attach biotin to the 5'-phosphate of an oligonucleotide. The reported yields of 50-70% are below that needed for use in automatic synthesizers, and the carbodiimide can cause unwanted modifications to oligonucleotide bases in the course of the reaction.

Smith et al, in "Synthesis of Oligonucleotides Containing an Aliphatic Amino Group at the 5' Terminus: Synthesis of Fluorescent DNA Primers for Use in DNA Sequence Analysis," Nucleic Acids Research, 40 Vol.13, pgs. 2399-2412 (1985), disclose a protected amino-derivatized nucleoside phosphoramidite for linking fluorescent or colorimetric tags to oligonucleotide fragments. While the linker is highly useful for attaching base-specific labels to the 5' terminus of oligonucleotides, the protected-amino phosphoramidite is not readily purified.

45 Connolly and Rider, in "Chemical Synthesis of Oligonucleotides Containing a Free Sulphydryl Group and Subsequent Attachment of Thiol Specific Probes," Nucleic Acids Research, Vol. 13, pgs. 4485-4502 (1985), disclose the synthesis of oligonucleotides having a trityl-protected sulphur attached via a two, three, or six carbon chain to the 5' phosphate of the oligonucleotide.

Apart from linking labeling agents to oligonucleotides, there is great interest in immobilizing various 50 molecules on polymer supports, such as catalysts, enzymes, microorganisms, affinity reagents, immunoabsorbents, and the like, for both preparative and analytical uses, e.g. Schott, Affinity Chromatography (Marcel Dekker, Inc., New York, 1984), and Mosbach, ed., Methods in Enzymology, Vol.44, "Immobilized Enzymes," (Academic Press, New York, 1976). Of particular interest in this field are means for immobilizing molecules and cells by covalent bonds.


Summary of the Invention

The compounds of the invention include novel linking agents comprising 2-substituted-3-protected-1,3,2-oxazaphosphacycloalkanes and their phosphoramidite precursors. The compounds of the invention further include conjugates of the above mentioned linking agents with oligonucleotides, conjugates of the above mentioned linking agents with polymer supports, and conjugates comprising dyes linked to oligonucleotides by the above mentioned linking agents. The present invention relates to compounds that are useful for linking organic moieties, such as fluorescent and chromogenic dyes, to DNA fragments and oligonucleotides, particularly single-stranded DNA and RNA, and for linking DNA fragments, oligonucleotides, proteins, and the like to polymer supports. The compounds and their conjugates are useful in automated and manual DNA and RNA synthesis and sequence analysis, construction of gene probes, affinity techniques, and the like. In particular, the cyclic embodiments of the linking agents of the invention advantageously overcome deficiencies associated with currently available linking methods by providing more readily purified linking agents.

15

Description of the Invention

The linking compounds of the present invention include 2-substituted-3-protected-1,3,2-oxazaphosphacycloalkanes defined by the formula:



35

Formula I

wherein:

n is in the range of 2 to 4, preferably in the range of 2 to 3, and most preferably is equal to 2.

R₁ represents an amino protection group, preferably either acid-labile or base-labile, e.g. as described by Green, in Protective Groups in Organic Synthesis (John Wiley & Sons, New York, 1981), chapter 7, which chapter is incorporated by reference. Preferably base-labile protection groups when taken together with the nitrogen of the heterocycle or that of its precursor, are base-labile amide and carbamate protection groups, preferably trihaloacetyl, acetoacetyl, and fluorenylmethyl carbamates, particularly 9-fluorenylmethyl carbamate and 9-(2-sulfo)-fluorenylmethyl carbamate, and most preferably trifluoroacetyl. Preferable acid-labile protection groups include trityl, and their lower (containing from 1-3 carbon atoms) alkoxy derivatives, particularly 4-monomethoxytrityl and 4,4'-dimethoxytrityl.


R₂ and R₃ are chosen so that (1) the likelihood that they sterically hinder the cyclization of the compound of Formula I is minimized, (2) the ring electron density of the heterocycle of Formula I is reduced, because it is thought that this will enhance the reactivity or the N-P bond in the compound of Formula I to hydroxyl groups, and (3) the molecular weight of the compound of Formula I is minimized to increase the likelihood that it can be purified by distillation. R₂ and R₃ taken separately each represent hydrogen, lower alkyl, lower substituted alkyl, particularly halo-, cyano-, or nitro-substituted lower alkyl, lower acyl, cyano, halo, and nitro; more preferably R₂ and R₃ taken separately each represent hydrogen, lower alkyl, and lower haloalkyl; and most preferably R₂ and R₃ represent hydrogens.

55

R₄ represents alkyl, alkenyl, aryl, aralkyl, or cycloalkyl containing up to 10 carbon atoms. More preferably, R₄ represents lower alkyl; electron-withdrawing beta-substituted ethyl, particularly beta-trihalomethyl-, beta-cyano-, beta-sulfo-, beta-nitro-substituted ethyl, or the like; electron-withdrawing substituted phenyl, particularly halo-, sulfo-, cyano-, or nitro-, substituted phenyl; or electron-withdrawing substituted phenylethyl. Most preferably, R₄ represents methyl, beta-cyanoethyl, or 4-nitrophenylethyl.

The term "lower alkyl" as used herein denotes straight-chain and branched-chain alkyl groups containing from 1-6 carbon atoms, e.g. methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, sec-butyl, neopentyl, tert-pentyl, and the like. "Lower substituted alkyl" denotes lower alkyl having electron-withdrawing substituents, such as halo, cyano, nitro, sulfo, or mono-, di-, or trihalomethyl, or the like. "Lower haloalkyl" denotes a lower alkyl with one or more halogen atom substituents, usually fluoro, chloro, bromo, or iodo. "Lower acyl" denotes an acyl containing from 1-7 carbon atoms wherein the non-double bonded carbons comprise a lower alkyl, possibly having halo-, cyano-, or nitro-substituents. "Electron-withdrawing" denotes the tendency of a substituent to attract valence electrons of the molecule of which it is apart, i.e. it is electronegative.

A special case of the above-described linking agent includes bicyclic compounds defined by the formula:




Formula II

wherein m is in the range of 1 to 3, and n, R₁, and R₄ are as defined above. More preferably m is in the range of 1 to 2; and most preferably m is 1. The lower cycloalkyl attached to the oxazaphosphorine-heterocycle is thought to introduce ring strain into the heterocycle making the nitrogen-phosphorous bond more reactive.

The linking compounds of the invention also include the phosphoramidite precursors to the above 2-substituted-3-protected-1,3,2-oxazaphosphacycloalkanes, the precursors being defined by the formula:

50

55



Formula III

wherein:


R₁, R₂, R₃, and R₄ are as indicated above:

²⁰ j is in the range of 2 to 10, more preferably in the range of 2 to 4, and most preferably j is in the range or 2 to 3 (it is believed that this latter range results in a precursor possessing the most favorable steric configuration for cyclization); and

R' and R'' taken separately each represent alkyl, aralkyl, cycloalkyl, and cycloalkylalkyl containing up to 10 carbon atoms. Preferably R' and R'' taken separately represent lower alkyl, and most preferably when the above phosphoramidites are used directly as linking agents, R' and R'' taken separately are sterically hindering lower alkyls which enhance the chemical stability of the phosphoramidites, and hence their shelf lives. Such sterically hindering lower alkyls include isopropyl, t-butyl, isobutyl, sec-butyl, neopentyl, tert-pentyl, isopentyl, sec-pentyl, and the like. Most preferably, when the above phosphoramidites are used as precursors to the above-described oxazaphospha-heterocycle, R' and R'' taken separately are isopropyl.

R' and R" taken together form an alkylene chain containing up to 5 carbon atoms in the principal chain and a total of up to 10 carbon atoms with both terminal valence bonds of said chain being attached to the nitrogen atom to which R' and R" are attached; or R' and R" when taken together with the nitrogen atom to which they are attached form a saturated nitrogen heterocycle which may contain one or more additional heteroatoms from the group consisting of nitrogen, oxygen, and sulfur. More preferably, R' and R" taken together and with the nitrogen to which they are attached represent pyrrolidino, morpholino, or piperidino. Most preferably, R' and R" taken together and with the nitrogen to which they are attached represent morpholino.

The phosphoramidite precursors to the above-described 2-substituted-3-protected-1,3,2-oxazaphosphacycloalkanes include substituted lower cycloalkanes defined by the formula:




Formula IV

wherein R₁, R₄, R', and R'' are as indicated above, and t is in the range of 0 to 8, and s is in the range of 0 to 8, subject to the condition that s+t is in the range of 1 to 8, more preferably t is in the range of 0 to 2, and s is in the range of 1 to 3, still more preferably t is 0 and s is in the range of 1 to 2, and most preferably t is 0 and S is 1.

Conjugates of the present invention include triester phosphite and triester and diester phosphate compounds of the formula:

6

10



15

Formula V

wherein:

20 i is 0 or 1 (where $i=0$ indicates phosphite, and $i=1$ indicates phosphate);
 k equals 1 (where $k=0$ indicates diester, and $k=1$ indicates triester) whenever i equals 0, or k equals 0 or 1 whenever i equals 1;

25 j, R_1 , R_2 , R_3 , and R_4 are as indicated above; and W represents an oligonucleotide, a polymer support, or an oligonucleotide linked to a polymer support. Oligonucleotides include fragments of single-stranded and double-stranded RNA, and fragments of single-and double-stranded DNA. Preferably the linking agent is conjugated to the terminal 5' carbon of an oligonucleotide, the terminal 3' carbon of an oligonucleotide, the terminal 2' carbon of RNA. More preferably, the linking agent is conjugated to the terminal 5' carbon of an oligonucleotide, and most preferably the linking agent is conjugated to the terminal 5' carbon of a fragment of single-stranded DNA.

30 Polymer supports may have a variety of forms and compositions. The polymer support can be derived from naturally occurring materials, naturally occurring materials which are synthetically modified, and synthetic materials. Of particular interest are polysaccharides, particularly crosslinked polysaccharides, such as agarose, which is available as Sepharose, dextran, available as Sephadex and Sephacyl, cellulose, starch and the like (Sepharose, Sephadex, and Sephacyl being trademarked products of Pharmacia Fine Chemicals). Other materials include polyacrylamides, polystyrenes, polyvinyl alcohols, copolymers of hydroxyethyl methacrylate and methyl methacrylate, silicones, teflons glasses, cells, or the like. In addition to solid supports in the form of particles and the like, the polymer support may also be in the form of liquid particles comprising a lipophilic or amphiphilic membrane, which serves to contain an internal fluid and define a space. Such particles include vesicles, cells, and liposomes. Preferably A' represents an insoluble polymer support having hydroxyl functionalities. The linking agents of the invention are attached to polymer supports having hydroxyl functionalities by following the procedures generally described below for attaching the linking agents to oligonucleotides.


The bracket on the lefthand side of Formula V (enclosing H and R_1) indicates that this embodiment includes both the protected and deprotected forms of the compound.

45 Oligonucleotides are linked to polymer supports by standard techniques of affinity chromatography or, for example, by linking means disclosed by Caruthers et al. in U.S. Patents 4,458,066 and 4,415,732 or the like.

The triester phosphite and triester and diester phosphate conjugates of the present invention further include compounds of the formula:

50

55




18

Formula VI


wherein i, k, s, t, R₁, R₄, and W are as indicated above.

Generally the triester phosphate compounds of the invention are readily obtained from the above-defined phosphite conjugates by oxidation, e.g. with the use of I₂ in water, 2,6-lutidine and tetrahydrofuran. Oxidation is extremely rapid (1-2 minutes).

The diester phosphate conjugates of the invention are readily obtained from the above-defined triester phosphates by standard techniques, for example when R₄ is methyl, the diester phosphates are obtained from the triester phosphates by treatment with thiophenol/triethylamine for about 30 minutes. The general procedure for synthesizing the phosphoramidite precursors of Formulas III and IV comprises the following steps. Halo-substituted-N,N-di-substituted-O-substituted phosphine, defined by the formula:



wherein X is a halogen, usually chloro, and R¹, R², and R₄ are as indicated above, is reacted with an amino-protected alcohol amine defined by the formula:



wherein R₁, R₂, and R₃ are as indicated above, in an aprotic solvent, such as dichloromethane, or the like, containing a non-nucleophilic base, for example a trialkylamine, such as N,N-diisopropylethyl amine, or the like, which absorbs the halogen acid released during the reaction. Preferably the reaction takes place under an inert atmosphere, such as argon. Acid conditions in the reaction mixture should be avoided as acid causes the amine of the phosphoramidite product to protonate, and thereby become reactive. The non-nucleophilic base reduces the likelihood of side reactions between the base and activated phosphoramidites.

Whenever the alkyl moiety, i.e. $-(CR_2R_3)_n-$, of the amino-protected alcohol amine is cycloalkyl, e.g. as in Formula IV, the amide or carbamate moiety of the alcohol amine is preferably in the cis configuration with the hydroxy; otherwise, formation of the oxazaphosphaheterocycle becomes unlikely, or even impossible, because of the spacial separation of the two groups.

After reacting the above materials, the reaction mixture, hereinafter referred to as the first reaction mixture, is washed with a mildly basic solution to remove salts of the non-nucleophilic base. Finally, the first reaction mixture is dried, e.g. with MgSO₄, Na₂SO₄, or the like, to give the phosphoramidite precursor.

The heterocycles of Formulas I and II are obtained by heating the appropriate precursor represented by Formulas III or IV, respectively, to form a second reaction mixture, and then separating the heterocycle from the mixture. The necessary amount of heating, i.e. temperature and duration, varies with different embodiments of the invention, preferably heating includes raising the precursor to a temperature within the range of about 25 to 250 °C, more preferably from about 25 to 150 °C, and most preferably from about 25 to 100 °C. The choice of method of separation depends on the nature of the substituent groups, R₁, R₂, R₃, and R₄. For example, as a rough approximation when the aggregate molecular weight of the substituents is sufficiently low, the steps of heating and separating can be accomplished by distilling. Other methods of separation include crystallization and chromatography. Preferably conjugates of oligonucleotides and linking agents of the invention are formed by attaching the linking agent to oligonucleotides synthesized by the solid phase synthetic methods developed by Caruthers and his coworkers, e.g. Caruthers et al., pgs. 1-17, in Genetic Engineering, Vol. 4, Setlow and Holleander, Eds. (Plenum Press, New York, 1982), and Caruthers et al., U.S. Patent 4,458,086. Attachment of the linking agent occurs as the final step in the synthetic process; that is, the linking agent is attached to the oligonucleotide as if it were a nucleotide subunit in the Caruthers et al. method.

The following examples serve to illustrate the present invention. The concentrations of reagents, temperatures, and values of other variable parameters are only to exemplify the application of the present invention and are not to be considered as limitations thereof.

EXAMPLE I. Synthesis of the phosphoramidite precursor of 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane

Chloro-N,N-diisopropylaminomethoxy phosphine (5.0 ml, available from Aldrich Chemical Co., Milwaukee, WI) was added dropwise at 0 °C to a stirred solution of N-(2-hydroxyethyl)-2,2,2-trifluoroacetamide (3.9 g) and diisopropylethylamine (5.0 ml) in dichloromethane (about 40 ml) under argon. (N-(2-hydroxyethyl)-2,2,2-trifluoroacetamide is synthesized following the procedures disclosed by Lazarus and Benkovic in J. Am. Chem. Soc., Vol. 101, pgs. 4300-4312 (1979); Ethyl trifluoroacetate (56.8g, 0.4 mol) in 50 mL of chloroform is added dropwise to a stirred solution of 24.4 g (0.4 mol) of ethanalamine in 50 mL of chloroform. The solution is stirred at room temperature for 5 h, rotary evaporated to remove the solvent, and distilled at 115 °C (4.3 Torr) to give 58.5 g of oil that crystallized upon scratching.) After stirring at room temperature for 0.5 hours the reaction mixture was washed twice with 0.2 M potassium carbonate solution and once with brine, dried (MgSO₄), and concentrated under reduced pressure to give N-(2-(N',N'-diisopropylaminomethoxyphosphinyloxy)ethyl)-2,2,2-trifluoroacetamide as a colorless liquid (7.77 g). ¹H-NMR (CD₂Cl₂): δ 3.6 (6H, m), 3.4 (3H, d, J = 12), 1.2 (12H, d, J = 6.5). ³¹P-NMR (CD₂Cl₂, ¹H decoupled): δ 149(s).

40

EXAMPLE II. Synthesis of the phosphoramidite precursor of 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclohexane

Chloro-N,N-diisopropylaminomethoxy phosphine (3.7 ml) was added dropwise at 0 °C to a stirred solution of N-(3-hydroxypropyl)-2,2,2-trifluoroacetamide (2.9 g, synthesized from 3-amino-1-propanol and ethyltrifluoroacetate in a manner similar to that disclosed by Lazarus and Benkovic, J. Amer. Chem. Soc., Vol.101, pgs. 4300-4312 (1979)) and diisopropylethylamine (3.7 ml) in dichloromethane (about 20 ml) under argon. After stirring at room temperature for 3 hours, the reaction mixture was poured into hexane (100 ml) and stirred. The mixture was allowed to settle and the supernatant was separated and concentrated under reduced pressure to give N-(3-(N',N'-diisopropylaminomethoxyphosphinyloxy)propyl)-2,2,2-trifluoroacetamide as a colorless liquid (5.2 g). ³¹P-NMR (CH₂Cl₂, ¹H decoupled): δ 149 (s)

55

EXAMPLE III. Synthesis of 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane

N-(2-(N',N'-diisopropylaminomethoxyphosphinyloxy)-ethyl)-2,2,2-trifluoroacetamide (7.7 g) was distilled (58-59 °C at 0.8 Torr) to quantitatively yield 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane as a colorless liquid.

5 IR (film): 1705, 1420, 1230, 1200, 1160, 1020, 965 cm⁻¹
 ¹H-NMR (CD₂Cl₂): δ 4.45 (2H, m), 3.65 (2H, m), 3.60 (3H, d, J = 12)
 ³¹P-NMR (CD₂Cl₂, ¹H-decoupled): δ 132(s), 125 (q, J = 61)
 MS: m/e 217 (M⁺), 197, 148, 138, 123, 120, 109, 92, 79, 70(100), 69, 62

10

EXAMPLE IV. Attaching 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane to the 5' terminus of an oligonucleotide

15 Attachment of 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane to a 5' hydroxyl of an oligonucleotide was performed on an Applied Biosystems 380A DNA synthesizer (Applied Biosystems, Foster City, CA), or comparable instrument. Caruthers et al., U.S. Patent 4,458,066; Caruthers et al., U.S. Patent 4,415,732; and Caruthers et al., "New Methods for Synthesizing Deoxyoligonucleotides," in Genetic Engineering, Vol. 4, pgs. 1-17 (Plenum Press, New York, 1982) provide detailed descriptions of the chemistry used by the Applied Biosystems 380A DNA synthesizer. Accordingly, these references are incorporated by reference for those descriptions. 2-Methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane was used as a 0.2 M acetonitrile solution in combination with 0.5 M tetrazole/acetonitrile solution to form an activated reagent in the synthesis cycle. The normal synthesizer cycle was modified only during the addition of the activated reagent in the following manner. The activated reagent was added twice with 1 hour wait times after each addition. The coupling yields were about 95%. Normal deprotection with thiophenol/triethylamine and then ammonium hydroxide gave a 5'-aminoethylphosphate oligonucleotide. Similar yields were obtained when the activated reagent comprised an acetonitrile solution containing 0.2 M 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane and 0.1 M 4-dimethylaminopyridine. In this case the modified activator reagent was added once, and allowed to react for about 15 minutes.

30

EXAMPLE V. Attaching 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane to the 3' terminus of an oligonucleotide

35 Attachment is accomplished in substantially the same manner as described in Example IV, except the oligonucleotide is synthesized in the 3' direction in accordance with the procedure generally described in Caruthers et al., U.S. Patent 4,458,066 (Roughly the difference is that the oligonucleotide is synthesized from 5' N,N-diisopropylaminophosphoramidites of 3'-protected nucleosides instead of 3' N,N-diisopropylaminophosphoramidites of 5'-protected nucleosides. Alternatively, the oligonucleotide is synthesized in the 3' direction using the phosphotriester method of Khorana and Itakura (i.e., Khorana, Science, Vol. 203, pgs. 614-625 (1979); Itakura et al. J. Biol. Chem., Vol. 250, pgs. 4592-4600, both of these references being incorporated by reference), or its modification by others, for example Letsinger and Mahaderan, J. Am. Chem. Soc., Vol. 87, pgs. 3526-(1965). In any case the linking agent is attached as a final addition in place of a nucleotide.

45

EXAMPLE VI. Attaching Fluorescein isothiocyanate (FITC) to a 5' aminoethylphosphate oligonucleotide

50 A dimethylformamide solution of fluorescein-6-isothiocyanate (25 microliters at a concentration of 10 mg/ml, e.g. available from Molecular Probes, Inc., Junction City, OR) was added to a solution of 5'-aminoethylphosphate TCCCAGTCACGACGTT (0.020 micromole, unpurified material being made on an Applied Biosystems 380A DNA synthesizer; here T = thymidine, C = cytidine, G = guanosine, and A = adenosine) in water (200 microliters) and 1 M NaHCO₃/Na₂CO₃ buffer, pH 9.0 (25 microliters). The resulting solution was stored in the dark at room temperature for at least 6 hours. To remove the unconjugated dye, the reaction mixture was passed through an equilibrated 10 ml Sephadex (trademark of

Pharmacia Fine Chemicals) G-25 (medium) column with water. The band of colored material in the excluded volume was collected. The crude 5'-fluorescein aminoethylphosphate oligonucleotide was purified by HPLC (e.g. Perkin-Elmer Series 4, or comparable instrument) on a Vydac C18 column (No. 218TP54), or the like, in a linear gradient of 10-20% acetonitrile/0.1 M triethylammonium acetate, pH 7.0.

5

Claims


1. A compound of the formula:

10

15

20

25



wherein:

30 n is in the range of 2 to 4;
 R₁ is an amino protection group;
 R₂ and R₃ taken separately each represent hydrogen, lower alkyl, lower substituted alkyl, lower cycloalkyl, lower acyl, cyano, halo, or nitro; and
 R₄ is alkyl, alkenyl, aryl, aralkyl, or cycloalkyl containing up to 10 carbon atoms.

35 2. A compound according to Claim 1 wherein n is in the range of 2 to 3.

3. A compound according to Claim 2 wherein R₁ taken together with the nitrogen to which it is attached represents a base-labile amide or carbamate protection group, and R₄ represents lower alkyl, electron-withdrawing beta-substituted ethyl, electron-withdrawing substituted phenylethyl, or electron-withdrawing substituted phenyl.

40 4. A compound according to Claim 3 wherein R₄ represents lower alkyl; beta-trihalomethyl-beta-nitro-, beta-sulfo-, or beta-cyano-substituted ethyl; halo-, nitro-, sulfo-, or cyano-substituted phenyl; or halo-, nitro-, sulfo-, or cyano-substituted phenylethyl.

5. A compound according to Claim 4 wherein R₄ is methyl, beta-cyanoethyl, or 4-nitrophenoxyethyl.

6. A compound according to Claim 5 wherein R₄ is methyl, or beta-cyanoethyl.

45 7. A compound according to Claim 3 wherein R₁ is trihaloacetyl, acetoacetyl, or fluorenylmethyl carbamate.

8. A compound according to Claim 7 wherein R₄ is lower alkyl; beta-trihalomethyl-, beta-nitro-, beta-cyano-, or beta-sulfo-substituted ethyl; halo-, nitro-, cyano-, or sulfo-substituted phenyl; or halo-, nitro-, cyano-, or sulfo-substituted phenylethyl.

9. A compound according to Claim 8 wherein R₄ is methyl, beta-cyanoethyl, or 4-nitrophenoxyethyl.

50 10. A compound according to Claim 9 wherein R₄ is methyl, or beta-cyanoethyl.

11. A compound according to Claim 7 wherein R₁ is trifluoroacetyl, acetoacetyl, 9-(2-sulfo)-fluorenylmethyl carbamate, or 9-fluorenylmethyl carbamate.

12. A compound according to Claim 11 wherein R₄ is methyl, beta-cyanoethyl, or 4-nitrophenoxyethyl, and wherein R₂ and R₃ are hydrogens.

55 13. A compound according to Claim 12 wherein R₁ is trifluoroacetyl or acetoacetyl, and wherein R₄ is methyl or beta-cyanoethyl.

14. A compound according to Claim 2 wherein R₁ is an acid-labile amino protection group.

15. A compound according to Claim 14 wherein R₄ is lower alkyl; beta-trihalomethyl-, beta-nitro-, beta-sulfo-, or beta-cyano-substituted ethyl; halo-, nitro-, cyano-, or sulfo-substituted phenyl; or halo-, nitro-, cyano-, or sulfo-substituted phenylethyl.

16. A compound according to Claim 15 wherein R₁ is trityl or lower alkoxy-substituted trityl.

17. A compound according to Claim 16 wherein R₁ is 4-monomethoxytrityl or 4,4'-dimethoxytrityl.


18. A compound according to Claim 17 wherein R₄ is methyl or beta-cyanoethyl.

19. 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane.

20. 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclohexane.

21. A compound of the formula:

10



wherein:

m is in the range of 1 to 3.

n is in the range of 2 to 3:

35 B₁ is an amino protection group; and

R₁ is alkyl, alkenyl, aryl, aralkyl, or cycloalkyl containing up to 10 carbon atoms.

22. A compound according to Claim 21 wherein:

m is in the range of 1 to 2.

n is 2.

40 R₁ taken together with the nitrogen atom to which it is attached represents a base-labile amide or carbamate protection group; and

R₄ represents lower alkyl; beta-trihalomethyl-, beta-cyano-, beta-nitro-, or beta-sulfo-substituted ethoxy-; nitro-, cyano-, or sulfo-substituted phenyl; or halo-, nitro-, cyano-, or sulfo-substituted phenylethyl.

23. A compound according to Claim 22 wherein R₁ is trihalo-45 carbamate and R₂ is methyl, beta-cyanethyl or 4-nitrobutyl.

24. A compound according to Claim 23 wherein R₁ is trifluoroacetyl, or acetoacetyl, and R₄ is methyl or beta-cyanethyl.

25. A compound according to Claim 21 wherein:
 m is in the range of 1 to 3;

m is in the range of 1 to 2;
 n is 0;

R is an acid-labile amine -

R_1 is an


R₄ is lower alkyl; beta-trihalomethyl-,beta-cyan-

26. A compound according to Claim 25 wherein R_1 is trityl or lower alkoxy-substituted trityl, and R_4 is the same as defined in claim 25.

27. A compound according to Claim 26

R₄ is methyl or beta-cyanoethyl.

28. A compound of the formula:



wherein:

j is in the range of 2 to 10;

R₁ is an amino protection group;

15 R₂ and R₃ taken separately each represent hydrogen, lower alkyl, lower substituted alkyl, lower cycloalkyl, lower acyl, cyano, halo, or nitro;

R₄ is alkyl, alkenyl, aryl, aralkyl, or cycloalkyl containing up to 10 carbon atoms;

R' and R" taken separately each represent alkyl, aryl, aralkyl, cycloalkyl, or cycloalkylalkyl containing up to 10 carbon atoms; and

20 R' and R" taken together form an alkylene chain containing up to 5 carbon atoms in the principal chain and a total of up to 10 carbon atoms with both terminal valence bonds of said chain being attached to the nitrogen atom to which R' and R" are attached; or R' and R" when taken together with the nitrogen atom to which they are attached form a saturated nitrogen heterocycle.

29. A compound according to Claim 28 wherein j is in the range of 2 to 4.

30. A compound according to Claim 29 wherein j is in the range of 2 to 3.

25 31. A compound according to Claim 30 wherein R₁ taken together with the nitrogen to which it is attached represents a base-labile amide or carbamate protection group, and R₄ represents lower alkyl, electron-withdrawing beta-substituted ethyl, electron-withdrawing substituted phenyl, or electron-withdrawing substituted phenylethyl.

32. A compound according to Claim 31 wherein R₄ is lower alkyl; beta-trihalomethyl-, beta-cyano-, beta-nitro-, or beta-sulfo-substituted ethyl; halo-, cyano-, nitro-, or sulfo-substituted phenyl; or halo-, cyano-, nitro-, or sulfo-substituted phenylethyl.

33. A compound according to Claim 32 wherein R₄ is methyl, 4-nitrophenylethyl, or beta-cyanoethyl.

34. A compound according to Claim 31 wherein R₁ is trihaloacetyl, acetoacetyl, or fluorenylmethyl carbamate.

35. A compound according to Claim 34 wherein R₄ is lower alkyl; beta-trihalomethyl-, beta-cyano-, beta-nitro-, or beta-sulfo-substituted ethyl; halo-, cyano-, nitro-, or sulfo-substituted phenyl; or halo-, cyano-, nitro-, or sulfo-substituted phenylethyl.

36. A compound according to Claim 35 wherein R₄ is methyl, 4-nitrophenylethyl, or beta-cyanoethyl.

37. A compound according to Claim 36 wherein R₁ is trifluoroacetyl, acetoacetyl, 9-(2-sulfo)-fluorenyl-methyl carbamate, or 9-fluorenylmethyl carbamate.

38. A compound according to Claim 37 wherein R' and R" taken separately are sterically hindering lower alkyls, and R' and R" taken together with the nitrogen atom to which they are attached is morpholino, pyrrolidino, or piperidino.

39. A compound according to Claim 38 wherein R' and R" taken separately are isopropyls, and R' and R" taken together is morpholino.

40. A compound according to Claim 39 wherein R₂ and R₃ are hydrogens.

41. A compound according to Claim 30 wherein R₁ is an acid-labile amino protection group.

42. A compound according to Claim 41 wherein:

45 R₁ is trityl or lower alkoxy-substituted trityl;


50 R₄ is lower alkyl; beta-cyano-, beta-trihalomethyl-, beta-nitro-, or beta-sulfo-substituted ethyl; halo-, cyano-, nitro-, or sulfo-substituted phenyl; or halo-, cyano-, nitro-, or sulfo-substituted phenylethyl;

R' and R" taken separately are sterically hindering lower alkyls; and

R' and R" taken together with the nitrogen atom to which they are attached is morpholino, pyrrolidino, or piperidino.

55 43. A compound according to Claim 42 wherein R₁ is 4-monoimethoxytrityl or 4,4'-dimethoxytrityl.

44. A cycloalkane of the formula:



the cycloalkane having a protected amino substituent and a phosphoramidite substituent wherein: s is in the range of 0 to 8, t is in the range of 0 to 8, and s+t is in the range of 1 to 8; R₁ is an amino protection group;

R₁ is an amino protection group;

R₄ is alkyl, alkenyl, aralkyl, or cycloalkyl containing up to 10 carbon atoms;

¹⁵ R' and R" taken separately are sterically hindering lower alkyls; and

R' and R" taken together with the nitrogen atom to which they are attached is morpholino, pyrrolidino, or piperidino.

45. A compound according to Claim 44 wherein s is in the range of 1 to 3, t is in the range of 0 to 2, and the protected amine and phosphoramidite substituents to the cycloalkane defined by said formula are in cis configuration.

46. A compound according to Claim 45 wherein R₁ taken together with the nitrogen atom to which it is attached represents a base-labile amide or carbamate protection group, and R₄ represents lower alkyl.

²⁵ *R* represents electron-donating alkyl, electron-donating substituted alkyl, electron-donating phenyl, or electron-donating substituted phenyl; *R'* represents electron-withdrawing group, and *R''* represents electron-alkyl, electron-withdrawing beta-substituted ethyl, electron-withdrawing substituted phenyl, or electron-withdrawing substituted phenylethyl.

47. A compound according to Claim 46 wherein R₁ is trihaloacetyl, acetoacetyl, or fluorenylmethyl carbamate.

48. A compound according to Claim 47 wherein:

t is 0;

s is in the range of 1 to 2;

³⁰ R₁ is trifluoroacetyl or acetoacetyl;

R₄ is methyl, 4-nitrophenyl, or beta-cyanethyl.

B' and B" taken separately are isopropyl; and

R' and R'' taken together with the nitrogen atom to which they are attached is morpholine.

R and R taken together with the nitrogen atom to which they are attached is morpholino.


49. A compound according to Claim 45 wherein
50. A compound according to Claim 49 wherein

50. A compound according to Claim 49 wherein:
 R_4 is lower alkyl, electron-withdrawing beta-substituted ethyl, electron-withdrawing substituted phenyl, or electron-withdrawing substituted phenylethyl; R' and R'' taken separately represent sterically hindering lower alkyls; and

40 R' and R'' taken together with the nitrogen atom to which they are attached represents morpholino, pyrrolidino, or piperidino.

51. A compound according to Claim 50 wherein t is 0, s is in the range of 1 to 2, and R₁ is trityl or alkoxy-substituted trityl.

52. A compound according to G



wherein:

I is 0 or 1;

J is in the range of 2 to 10;

k is 1 whenever i is 0, or k is 0 or 1 whenever i is 1;

5 R₁ is an amino protection group;

R₂ and R₃ taken separately each represent hydrogen, lower alkyl, lower substituted alkyl, lower cycloalkyl, lower acyl, cyano, halo, or nitro;

R₄ is alkyl, alkenyl, aryl, aralkyl, or cycloalkyl containing up to 10 carbon atoms; and

W represents an oligonucleotide, polymer support, or an oligonucleotide linked to a polymer support.

10 54. A compound according to Claim 53 wherein R₂ and R₃ are hydrogens, and R₄ is lower alkyl, electron-withdrawing beta-substituted ethyl, electron-withdrawing substituted phenyl, or electron-withdrawing substituted phenylethyl.

55. A compound according to Claim 54 wherein j is in the range of 2 to 4.

56. A compound according to Claim 55 wherein W is an oligonucleotide.

15 57. A compound according to Claim 56 wherein R₁ taken together with the nitrogen atom to which it is attached is a base-labile carbamate or amide protection group.

58. A compound according to Claim 57 wherein R₁ is trihaloacetyl, acetoacetyl, or fluorenylmethyl carbamate.

59. A compound according to Claim 58 wherein R₁ is an acid-labile amino protection group.


20 60. A compound according to Claim 59 wherein R₁ is trityl or lower alkoxy-substituted trityl.

61. A compound according to Claim 55 wherein W is a polymer support.

62. A compound according to Claim 61 wherein said polymer support is a cross-linked polysaccharide.

63. A compound according to Claim 62 wherein said cross-linked polysaccharide is selected from the group consisting of dextran, cellulose, and agarose.

25 64. A compound of the formula:



40 wherein:

R₁ is an amino protection group;

s is in the range of 0 to 8, t is in the range of 0 to 8, and s+t is in the range of 1 to 8;

R₄ represents lower alkyl; electron-withdrawing beta-substituted ethyl; electron-withdrawing substituted phenyl; or electron-withdrawing substituted phenylethyl; i is 0 or 1;

45 k is 1 whenever i is 0, or k is 0 or 1 whenever i is 1; and

W is an oligonucleotide, a polymer support, or an oligonucleotide linked to a polymer support.

65. A compound according to Claim 64 wherein t is in the range of 0 to 2, s is in the range of 1 to 3.

66. A compound according to Claim 65 wherein W is an oligonucleotide.

67. A compound according to Claim 66 wherein R₁ taken together with the nitrogen atom to which it is attached is a base-labile amide or carbamate protection group.

68. A compound according to Claim 67 wherein R₁ is trihaloacetyl, acetoacetyl, or fluorenylmethyl carbamate.

69. A compound according to Claim 68 wherein t is 0, s is in the range of 1 to 2.

70. A compound according to Claim 68 wherein t is in the range of 0 to 2, s is in the range of 1 to 3, and R₁ is an acid-labile amino protection group.

71. A compound according to Claim 70 wherein R₁ is trityl or lower alkoxy-substituted trityl.

72. A compound according to Claim 65 wherein W is a polymer support.

73. A compound according to Claim 72 wherein said polymer support is a cross-linked polysaccharide.

74. A method of synthesizing 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkanes, the method comprising the steps of:
 heating a phosphoramidite precursor to form a reaction mixture containing a 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane; and
 5 separating the 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane from the reaction mixture.

75. The method according to Claim 74 further including the steps of:
 reacting a halo-substituted-N,N-di-substituted-lower alkoxy phosphine with an amino-protected alcohol amine in an aprotic solvent to form a first reaction mixture containing said phosphoramidite precursor; and
 separating said phosphoramidite precursor from the first reaction mixture.

10 76. The method according to Claim 75 wherein said step of heating includes heating to a temperature in the range of about 25-250 °C.

77. The method according to Claim 76 wherein said step of heating includes heating to a temperature in the range of about 25-150 °C.

15 78. The method according to Claim 77 wherein said step of heating includes heating to a temperature in the range of about 50-100 °C.

79. The method according to Claim 75 wherein said step of separating said 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane includes distilling.

80. The method according to Claim 79 wherein said 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane is 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclopentane or 2-methoxy-3-trifluoroacetyl-1,3,2-oxazaphosphacyclohexane.

20 81. A method of labeling an oligonucleotide, comprising the steps of:
 reacting a 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane linking agent with an unprotected hydroxyl of the oligonucleotide to form a linker-oligonucleotide conjugate, the 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane linking agent having a protected amine;
 25 deprotecting the protected amine; and reacting a label with the deprotected amine.

82. The method according to Claim 81 further including the step of synthesizing said oligonucleotide by a solid phase synthesis procedure, and wherein said step of reacting a 2-lower alkoxy-3-protected-1,3,2-oxazaphosphacycloalkane is accomplished as a final addition step in said solid phase synthesis procedure.

30

35

40

45

50

55



DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X	CHEMICAL ABSTRACTS, vol. 91, 13th-20th August 1979, page 719, column 2, abstract no. 57094s, Columbus, Ohio, US; V.V. KUROCHKIN et al.: "Synthesis of N-(trialkylsilyl)-1,3,2-oxazaphosphorinanes", & ZH. OBUKHCH. KHIM. 1979, 49(3), 711	1	C 07 F 9/65 C 07 F 9/24 C 08 F 8/40 C 07 H 21/00
A	--- CHEMICAL ABSTRACTS, vol. 81, no. 11, 16th September 1974, page 484, column 1, abstract no. 63723f, Columbus, Ohio, US; M.A. PUDOVIK et al.: "Synthesis of N-acetylated 1,3,2-oxaazaphospholanes", & ZH. OBUKHCH. KHIM. 1974, 44(5), 1020-1024	1	
A	--- CHEMICAL ABSTRACTS, vol. 74, no. 23, 7th June 1971, page 466, column 2 - page 467, column 1, abstract no. 125583b, Columbus, Ohio, US; A.N. PUDOVIK et al.: "2-Substituted N-phenyl- and N-benzyl-1,3,2-oxaazaphospholanes", & ZH. OBUKHCH. KHIM. 1970, 40(7), 1477-1480	1	C 07 F 9/65 C 07 F 9/24 C 07 H 21/00 C 08 F 8/40
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
BERLIN	29-05-1987	KAPTEYN H G	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone	T : theory or principle underlying the invention		
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date		
A : technological background	D : document cited in the application		
O : non-written disclosure	L : document cited for other reasons		
P : intermediate document	& : member of the same patent family, corresponding document		



DOCUMENTS CONSIDERED TO BE RELEVANT			Page 2
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	JOURNAL OF CHEMICAL SOCIETY PERKINS TRANSACTIONS I, 1985, pages 199-202; A.S. JONES et al.: "Synthesis of some nucleoside cyclic phosphoramidates and related compounds via phosphoramidites"	1	
A	FR-A-2 556 726 (CALIFORNIA INSTITUTE OF TECHNOLOGY)	81	
A	US-A-4 401 796 (K. ITAKURA)	82	
D,A	US-A-4 458 066 (M.H. CARUTHERS et al.)	53	
D,A	US-A-4 415 732 (M.H. CARUTHERS et al.)	53	TECHNICAL FIELDS SEARCHED (Int. Cl.4)
D,A	NUCLEIC ACIDS RESEARCH, vol. 13, 1985, pages 2399-2412;	1,81	
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
BERLIN	29-05-1987	KAPTEYN H G	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone			
Y : particularly relevant if combined with another document of the same category			
A : technological background			
O : non-written disclosure			
P : intermediate document			